NCT00057525View on ClinicalTrials.gov

A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

April 30, 2004

Study Completion Date

August 31, 2004

Conditions
Anthrax
Interventions
BIOLOGICAL

Anthrax

Doses will range from 5 \_g to 100 \_g rPA, and at each dose-level, rPA will either be combined with phosphate-buffered saline (PBS) or adsorbed to Alhydrogel

BIOLOGICAL

Alhdryogel or PBS

Doses will range from 5 \_g to 100 \_g rPA, and at each dose-level, rPA will either be combined with phosphate-buffered saline (PBS) or adsorbed to Alhydrogel

Trial Locations (1)

20850

Walter Reed Army Institute of Research / Henry M. Jackson Foundation Vaccine Clinical Research Center, 1600 East Gude Dr, Rockville

All Listed Sponsors
lead

DynPort Vaccine Company LLC, A GDIT Company

INDUSTRY

NCT00057525 - A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults | Biotech Hunter | Biotech Hunter